Post-Pfizer Deal Setback, Ablynx Finds Data Differentiating Its Nanobody Ozoralizumab From Other Anti-TNFs
This article was originally published in The Pink Sheet Daily
Ablynx releases Phase II open-label extension clinical data showing its lead nanobody, ozoralizumab, allows individualized dosing in rheumatoid arthritis and doesn't induce neutralizing antibodies that affect efficacy, potentially differentiating it from marketed TNF inhibitors.
You may also be interested in...
Next-generation antibody company Ablynx boasts a series of technology partnership deals but its primary goal is to develop drugs. Can partners’ money fund a pipeline with sufficient focus to be manageable, but enough breadth to survive?
Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.